You are here

Biomarin

BioMarin's share prices fluctuate following Phase 3 clinical trial results

BioMarin's share prices fluctuate following Phase 3 clinical trial results

Yahoo/Investing.com

clinical trials

Flag link:

With Roctavian as a launching pad, BioMarin looks to up pace of new drug filings

With Roctavian as a launching pad, BioMarin looks to up pace of new drug filings

Fierce Biotech

drug development

Flag link:

Voxzogo saves the day for Biomarin

Voxzogo saves the day for Biomarin

EP Vantage

Flag link:

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

BioSpace

fibrodysplasia ossificans progressiva

Santhera Pharmaceuticals

Flag link:

PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics

PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics

Fierce Biotech

PTC Therapeutics

clinical trials

Flag link:

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

Forbes

Flag link:

BioMarin opens €38m expansion at Irish manufacturing site

BioMarin opens €38m expansion at Irish manufacturing site

Biopharma Reporter

drug manufacturing

Flag link:

BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia

BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia

BioSpace

Flag link:

FDA delays review of BioMarin's hemophilia gene therapy after data update

FDA delays review of BioMarin's hemophilia gene therapy after data update

Endpoints

Flag link:

JPM Day 1: Highlights

JPM Day 1: Highlights

BioSpace

Sarepta Therapeutics

Arrowhead Pharmaceuticals

Bristol Myers Squibb

Flag link:

5 FDA decisions to watch in the first quarter

5 FDA decisions to watch in the first quarter

BioPharma Dive

Alzheimer's disease

Acadia Pharmaceuticals

Gilead Sciences

Flag link:

BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests

BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests

Fierce Biotech

Flag link:

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Flag link:

BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain

BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain

BioPharma Dive

Flag link:

BioMarin lays off 120 employees to save $50M a year, with US operations hardest hit

BioMarin lays off 120 employees to save $50M a year, with US operations hardest hit

Fierce Biotech

Flag link:

BioMarin Banks on More Robust Data in Hemophilia A Resubmission

BioMarin Banks on More Robust Data in Hemophilia A Resubmission

BioSpace

valoctocogene roxaparvovec

Flag link:

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

BioSpace

Flag link:

BioMarin says PhIII gene therapy study participant's cancer is unrelated to therapy

BioMarin says PhIII gene therapy study participant's cancer is unrelated to therapy

Endpoints

clinical trials

Flag link:

Pages